TrialBMC cancer2018

Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial.

Tetsu Hayashida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.